Navigation Links
Cethrin in Medical News

Alseres Shares Begin Trading on the Pink Sheets OTC Market

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

...ed in December 2006 and amended in March 2007 (the cethrin License) was further amended. The Amendment repla...nd performance-related milestones contained in the cethrin License with a formula-based approach to sharing a...nt for the compounds and technology covered by the cethrin License. In the event that the Company fails to s...

Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres Pharmaceuticals, Inc. Announces $200,000 Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia Alseres Pharmaceuticals, Inc 50...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...ing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pha...

Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals,...

Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...yndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...

Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

...ful, this trial will provide us with evidence that cethrin is more effective than a placebo in treating acute...ur preliminary planning for the Phase IIb trial of cethrin called for us to enroll up to 100 subjects in 80 s...ropriate sites and investigators for the Phase IIb cethrin study expected to commence in the first quarter of...

Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...
Cethrin in Medical Technology

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage Level HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ -- Boston Life Sciences announced today that clinical data on its lead nerve repair therapy, Cethrin(R), were presented in the Neurotrauma and Critical Care Scientific Sess...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres ...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

... Analysis of the data by dose group indicates that cethrin doses of 1 and 3 mg appear to be the most benefici... ) "The safety and efficacy observations of the cethrin trial continue to be encouraging. Many patients ha...orward with its previously announced plans for the cethrin Phase IIb trial in acute spinal cord injury in the...

Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates

...eres may exercise an option to amend the Company's cethrin License Agreement. (Logo: http://www.newscom.co...ard for Alseres in realizing the full value of our cethrin spinal cord program and our Rho inhibitor technolo...cts in a Phase I/IIa clinical trial indicated that cethrin was safe and well tolerated. The overall populatio...

Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or ...

Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008

...ark Hurtt, Chief Medical Officer, will discuss the cethrin development program as a member of an expert panel...ion, Dr. Hurtt will present interim results of the cethrin Phase I/IIa clinical trial in acute spinal cord in...acy results from the first 37 patients in Alseres' cethrin Phase I/IIa study. The data indicated that...

Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

...ed enrollment in the Phase I/IIa clinical trial of cethrin in acute spinal cord injury (SCI). A total of 48 s...iously announced plans for the placebo-controlled, cethrin Phase IIb trial in acute spinal cord injury at sit...rope and other countries in 2008. "We believe that cethrin continues to be the most advanced drug candidate i...

Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

... DSMB's recommendation is an important step in the cethrin clinical plan," commented Dr. Mark Hurtt, Alseres'...understanding of the encouraging efficacy data for cethrin at lower doses, and provide additional safety data...ient enrollment in early 2008." About Cethrin(R) cethrin is a recombinant protein drug intended to facilita...
Cethrin in Biological Technology

Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. http://www.alseres.com/ Contact: Kenneth L. Rice 508...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

...8, in Washington, DC by Dr. Michael Fehlings, principal Investigator of the cethrin Phase I/IIa trial. -- We are pursuing development and commercialization p... no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. ...

Alseres Pharmaceuticals, Inc. Raises $5 Million

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pharmaceut...

Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights

...d Injury on the first 37 subjects treated with cethrin at doses up to 6 mg. The data indicated that cethrin was safe and well tolerated. The overall population of patients treated with cethrin demonstrated an improvement in their impairmen...

Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

...tegies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of cethrin and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "antic...

Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...

Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...
Other Tags
(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic Away" ... under control with a simple and efficient method. , ... new method as an anxiety recovery program which promises ... anxiety related disorders. , What makes this program ... can be accessed by users from the comfort of ...
(Date:8/30/2014)... Scotch Plains, NJ (PRWEB) August 30, 2014 ... the first facilities in New Jersey and even in ... in-demand technology that takes inches off of patients’ waists ... by freezing cells in small sections, Vanquish is more ... without pain. Patients lay comfortably under panels about ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... introduced low cost SEO service for small businesses. , ... or start-ups cannot afford costly search engine optimization service. ... budget of small businesses into account. , On ... said, “We have introduced this low cost SEO service ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Acne is a common problem millions of American cope with ... a daily nuisance, for some, it can have a crippling impact ... lead to dramatic mood swings and depression. , Those struggling ... their skin. In some cases, that can make the problem even ... those on a quest for clearer skin can now view ...
Breaking Medicine News(10 mins):Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
(Date:8/28/2014)... method for delivering compounds that could positively ... AIDS may be possible, thanks to researchers ... A semi-soft vaginal suppository made from the ... the antiviral drug Tenofovir provides a woman-initiated, ... spread of sexually transmitted infections during unprotected ...
(Date:8/28/2014)... than 25 million kilometres of new roads will be ... slice into Earth,s last wildernesses, where they bring an ... , Now, an ambitious study has created a ,global ... try to balance the competing demands of development and ... ,environmental-values, layer that estimates that natural importance of ecosystems ...
(Date:8/28/2014)... areas conserve biodiversity and more action is needed to ... researchers say. , Published in PLOS ONE , ... of Exeter, used meta-analysis - combining results from different ... of research into these areas, to determine whether they ... of Biological Sciences, said protecting an area from human ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Protected areas proven to protect biodiversity 2
Other Contents